ALGS 8-K 2026-11-06

Aligos Therapeutics, Inc. (ALGS) 8-K dated 2026-11-06 — accession 0001171843-26-007214.

Aligos Therapeutics, Inc. (ALGS) is a biotechnology company listed on US.

Aligos Therapeutics, Inc. filed a 8-K on 2026-11-06. Accession 0001171843-26-007214.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ALGS revenue for 2025-12-31 was $2.2M. Net income was -$24.2M. Revenue was down 39.5% from 2024-12-31 to 2025-12-31. ALGS currently screens at market cap $44.1M.

Not investment advice. The ALGS SEC hub lists recent forms. The stock page is the research view.